NCT05385406 HPV Screening With Triage by HPV Genotyping Versus Visual Inspection With Acetic Acid
| NCT ID | NCT05385406 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prof. Patrick Petignat |
| Condition | Cervical Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,500 participants |
| Start Date | 2022-12-06 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5,500 participants in total. It began in 2022-12-06 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa, despite the existence of effective prevention and screening methods. Because vaccination rates against human papillomavirus (causing nearly all cervical cancers) are still insufficient in some low-resource countries, early detection and treatment of cervical lesions at risk of progressing to cancer are crucial components of cervical cancer control. Therefore, it is essential to find the most reliable and appropriate screening strategy in the context of low-resource countries in order to identify women in need of treatment and thus prevent the development of cervical cancer. The objective of our study is to compare two different methods of cervical cancer screening adapted to low-resource settings, in two study centers in Cameroon.
Eligibility Criteria
Inclusion Criteria: * HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old * Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF). Exclusion Criteria: * Pregnancy at the time of screening * Previous hysterectomy * Known cervical cancer * Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass) * Conditions that can interfere with visualization of the cervix * Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure) * Women who are not able to comply with the study protocol.
Contact & Investigator
Patrick Petignat, PD
PRINCIPAL INVESTIGATOR
University Hospital, Geneva
Frequently Asked Questions
Who can join the NCT05385406 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 49 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05385406 currently recruiting?
Yes, NCT05385406 is actively recruiting participants. Contact the research team at patrick.petignat@hcuge.ch for enrollment information.
Where is the NCT05385406 trial being conducted?
This trial is being conducted at Dschang, Cameroon, Bafoussam, Cameroon.
Who is sponsoring the NCT05385406 clinical trial?
NCT05385406 is sponsored by Prof. Patrick Petignat. The principal investigator is Patrick Petignat, PD at University Hospital, Geneva. The trial plans to enroll 5,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.